
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
These strains differ from hospital-acquired strains in that they are more manageable and may respond to treatments to which they would appear to be resistant, according to their sensitivity cultures.






